Deborah Glasser: Nasdaq Bell Celebrating FDA Approval of Novel ITP Therapy
Deborah Glasser, Head of Specialty Care for Sanofi, shared a post on LinkedIn:
”Yesterday, I had the opportunity to ring the Nasdaq closing bell, surrounded by Sanofi colleagues and representatives from the Platelet Disorder Support Association – PDSA. I’m so grateful that PDSA joined us on this special occasion to celebrate ITP Awareness Month, and to recognize the recent FDA approval of a novel treatment. By targeting root causes through multi-immune modulation, this new medicine represents a significant step forward for patients living with immune thrombocytopenia (ITP), a complex immune dysregulation disease, which can cause symptoms that disrupt daily life.
This moment reflects the power of science, collaboration, and our shared commitment to improving patient outcomes. At Sanofi, we continue to push the boundaries of immunoscience to make a meaningful difference for individuals affected by rare conditions like ITP.”
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25